658 related articles for article (PubMed ID: 10553165)
41. [Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy].
Wrembel-Wargocka J; Jabłońska H; Chomiczewski K
Przegl Lek; 1996; 53(11):820-5. PubMed ID: 9173447
[TBL] [Abstract][Full Text] [Related]
42. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Altmann S; Hoffmanns H
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
[TBL] [Abstract][Full Text] [Related]
43. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
Capizzi RL
Semin Oncol; 1994 Oct; 21(5 Suppl 11):8-15. PubMed ID: 7973776
[TBL] [Abstract][Full Text] [Related]
44. Amifostine for protection from antineoplastic drug toxicity.
Foster-Nora JA; Siden R
Am J Health Syst Pharm; 1997 Apr; 54(7):787-800. PubMed ID: 9099346
[TBL] [Abstract][Full Text] [Related]
45. Preclinical evaluation of WR-151327: an orally active chemotherapy protector.
Green D; Bensely D; Schein P
Cancer Res; 1994 Feb; 54(3):738-41. PubMed ID: 8306335
[TBL] [Abstract][Full Text] [Related]
46. Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review).
Orditura M; De Vita F; Roscigno A; Infusino S; Auriemma A; Iodice P; Ciaramella F; Abbate G; Catalano G
Oncol Rep; 1999; 6(6):1357-62. PubMed ID: 10523712
[TBL] [Abstract][Full Text] [Related]
47. Clinical status of the new cytoprotective agent, amifostine.
Kalaycioglu M; Bukowski R
Oncology (Williston Park); 1994 Jul; 8(7):15-6, 19-20, 23. PubMed ID: 7522504
[TBL] [Abstract][Full Text] [Related]
48. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
Links M; Lewis C
Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
[TBL] [Abstract][Full Text] [Related]
49. Cytoprotective effects of amifostine in the treatment of childhood malignancies.
Cetingül N; Midyat L; Kantar M; Demirağ B; Aksoylar S; Kansoy S
Pediatr Blood Cancer; 2009 Jul; 52(7):829-33. PubMed ID: 19214974
[TBL] [Abstract][Full Text] [Related]
50. Amifostine, a reactive oxigen species scavenger with radiation- and chemo-protective properties, inhibits in vitro platelet activation induced by ADP, collagen or PAF.
Porta C; Maiolo A; Tua A; Grignani G
Haematologica; 2000 Aug; 85(8):820-5. PubMed ID: 10942928
[TBL] [Abstract][Full Text] [Related]
51. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
Bourhis J; Rosine D
Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
[TBL] [Abstract][Full Text] [Related]
52. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
Hensley ML; Hagerty KL; Kewalramani T; Green DM; Meropol NJ; Wasserman TH; Cohen GI; Emami B; Gradishar WJ; Mitchell RB; Thigpen JT; Trotti A; von Hoff D; Schuchter LM
J Clin Oncol; 2009 Jan; 27(1):127-45. PubMed ID: 19018081
[TBL] [Abstract][Full Text] [Related]
53. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.
Spencer CM; Goa KL
Drugs; 1995 Dec; 50(6):1001-31. PubMed ID: 8612469
[TBL] [Abstract][Full Text] [Related]
54. Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol).
Schuchter LM
Eur J Cancer; 1996; 32A Suppl 4():S40-2. PubMed ID: 8976821
[TBL] [Abstract][Full Text] [Related]
55. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects.
Peters GJ; van der Vijgh WJ
Eur J Cancer; 1995; 31A Suppl 1():S1-7. PubMed ID: 7577093
[TBL] [Abstract][Full Text] [Related]
56. Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study.
De Souza CA; Santini G; Marino G; Nati S; Congiu AM; Vigorito AC; Damasio E
Braz J Med Biol Res; 2000 Jul; 33(7):791-8. PubMed ID: 10881054
[TBL] [Abstract][Full Text] [Related]
57. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):3-21. PubMed ID: 10348255
[TBL] [Abstract][Full Text] [Related]
58. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.
Moore DH; Donnelly J; McGuire WP; Almadrones L; Cella DF; Herzog TJ; Waggoner SE;
J Clin Oncol; 2003 Nov; 21(22):4207-13. PubMed ID: 14615449
[TBL] [Abstract][Full Text] [Related]
59. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer.
Büntzel J; Glatzel M; Kuttner K; Weinaug R; Fröhlich D
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):4-13. PubMed ID: 11917277
[TBL] [Abstract][Full Text] [Related]
60. Reducing the toxicity of anticancer therapy: new strategies.
Griggs JJ
Leuk Res; 1998 May; 22 Suppl 1():S27-33. PubMed ID: 9734697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
